Consistently, SAA1 has been reported as a molecular/metabolic signature that can help identify patients are at high risk of malignant GBM and promotes glioma cells migration and invasion through integrin aVb3 (Lin et al., 2018). The gene discussed is SAA1; the disease is glioma.